Monograph Details
|
|
Immune System
> Immunization
|
|
AFLURIA |
| Manufacturer |
|
CSL Biotherapies |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Trivalent, inactivated, "split virus" influenza vaccine (Types A and B); formulation changes annually; susp for IM inj; may contain trace amounts of neomycin sulfate, polymyxin B. |
| Indications |
|
Influenza immunization. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
≥18yrs: 0.5mL by IM inj once in deltoid. |
| Contraindications |
|
Allergy to egg or chicken proteins, neomycin, polymyxin. Life-threatening reaction to any previous flu vaccine. |
| Precautions |
|
Use current formulation only. Have epinephrine inj (1:1000) available. Guillain-Barre syndrome within 6 weeks of previous flu vaccine. Immunosuppressed. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Concomitant vaccines: insufficient data (see literature). Immunosuppressants (eg, corticosteroids): may get suboptimal response. |
| Adverse Reactions |
|
Local reactions (eg, tenderness, redness, swelling, pain), headache, malaise, muscle aches. |
| Extra Text |
|
Note: To report adverse events to VAERS call (800) 822-7967. |
| How Supplied |
Single-dose prefilled syringe 0.5mL (preservative-free)—10 (without needles)
Multi-dose vial 5mL (contains thimerosal)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
